Trial Profile
A Phase 1, Multicenter, Open-Label, Dose Escalation Study of Tandutinib (Formerly MLN518) in Combination With Temozolomide and Bevacizumab Following Concurrent Radiation Therapy and Temozolomide in the Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2009
Price :
$35
*
At a glance
- Drugs Tandutinib (Primary) ; Bevacizumab; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 30 May 2009 New trial record